ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2014

Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond.

H S Rugo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.